<DOC>
	<DOCNO>NCT00309647</DOCNO>
	<brief_summary>Today , lead contender next pandemic influenza H5N1 , strain avian virus . Prevention control pandemic depend rapid production worldwide distribution specific pandemic vaccine . Candidate 'pandemic-like ' vaccine must develop tested clinical trial determine optimal formulation best vaccination schedule.This study design test healthy adult age 18-60 year reactogenicity immunogenicity one two administration candidate pandemic H5N1 vaccine formulate Whole Virus . The vaccine contain different antigen dos . For dose , adjuvanted vaccine compare plain vaccine order detect optimal formulation immunization H5N1 influenza strain .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity Pandemic Influenza Vaccine Adults Aged Between 18 60 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male female , include , 18 60 year age time first vaccination . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential . Exclusion criterion : Administration vaccine period start 15 day first administration study vaccine end 21 second one . Administration influenza vaccine study vaccine entire study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first administration study vaccine study . lactate woman Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior first vaccination , plan use study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>prophylaxis pandemic influenza</keyword>
</DOC>